Boundless Bio, Inc. Common Stock Total Assets
Boundless Bio, Inc. Common Stock total assets. Based on the latest financial reports, Boundless Bio, Inc. Common Stock (BOLD) holds total assets worth $168.72 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Boundless Bio, Inc. Common Stock for the company's overall valuation and market capitalisation.
Total Assets of Boundless Bio, Inc. Common Stock (2016–2024)
Total assets of Boundless Bio, Inc. Common Stock from 2016 to 2024. This chart illustrates how Boundless Bio, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See BOLD stock price for real-time trading data and today's change.
Boundless Bio, Inc. Common Stock - Asset Composition Analysis
Boundless Bio, Inc. Common Stock Total Assets Breakdown (December 2024)
Boundless Bio, Inc. Common Stock total assets breakdown as of December 2024. Boundless Bio, Inc. Common Stock's total assets of $168.72 Million consist of 74.8% current assets and 25.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Boundless Bio, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Boundless Bio, Inc. Common Stock to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Boundless Bio, Inc. Common Stock's current assets represent 74.8% of total assets in 2024, a decrease from 76.3% in 2016.
- Cash Position: Cash and equivalents constituted 12.9% of total assets in 2024, down from 25.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Boundless Bio, Inc. Common Stock Competitors by Total Assets
Key competitors of Boundless Bio, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Boundless Bio, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.14 | 17.03 | 12.04 |
| Quick Ratio | 10.14 | 17.03 | 12.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $108.31 Million | $160.44 Million | $147.20 Million |
Boundless Bio, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Boundless Bio, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.23 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 58.9% |
| Total Assets | $206.41 Million |
| Market Capitalization | $25.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values Boundless Bio, Inc. Common Stock's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Boundless Bio, Inc. Common Stock's assets grew by 58.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Boundless Bio, Inc. Common Stock (2016–2024)
The table below shows the annual total assets of Boundless Bio, Inc. Common Stock from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $206.41 Million | +58.91% |
| 2023-12-31 | $129.89 Million | +69.07% |
| 2022-12-31 | $76.83 Million | -32.44% |
| 2021-12-31 | $113.72 Million | -75.94% |
| 2018-12-31 | $472.56 Million | +164.50% |
| 2017-12-31 | $178.66 Million | +25.77% |
| 2016-12-31 | $142.06 Million | -- |
About Boundless Bio, Inc. Common Stock
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene ampli… Read more